Lu Wusheng, Li Xiao, Wang Chaohua, Liu Wenxiu, Jiao He, Mo Tingshu, Chen Zhinan
Radiologic Department of West China Hospital, Sichuan University, Chengdu 610041.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2003 Dec;20(4):689-91.
Before 131I-HAb18F(ab')2 administration, 24 cases of mid-term or advanced hepatocellular carcinoma(HCC) were given Lugol's Liquid to block the thyroid gland, and submitted to hepatic colloid imaging. The cases were randomly divided into 3 groups. Then 131I-HAb18F(ab')2 was injected into the target hepatic artery with doses of 0.5, 0.75, 1.0 mCi/kg, respectively. At the followed 10, 48, 96 and 192 hours, 131I-HAb18F(ab')2 distribution in human body was acquired by whole body dynamic image with Single photon emission computed tomography(SPECT). The results showsed that 131I-HAb18F(ab')2 in tumor tissue was significantly higher than that in normal liver tissue and other organs. This difference became obvious as time passed. 131I-HAb18F(ab')2 is stable in human body and it can combine with HCC tissue specifically. So it is a new medicine deserving further research for the treatment of HCC.
在给予131I-HAb18F(ab')2之前，24例中晚期肝细胞癌（HCC）患者服用卢戈氏液阻断甲状腺，并进行肝胶体显像。将这些病例随机分为3组。然后分别以0.5、0.75、1.0 mCi/kg的剂量将131I-HAb18F(ab')2注入靶肝动脉。在随后的10、48、96和192小时，通过单光子发射计算机断层扫描（SPECT）全身动态显像获取131I-HAb18F(ab')2在人体内的分布情况。结果显示，肿瘤组织中的131I-HAb18F(ab')2明显高于正常肝组织和其他器官。随着时间推移，这种差异变得明显。131I-HAb18F(ab')2在人体内稳定，且能与HCC组织特异性结合。因此，它是一种值得进一步研究用于治疗HCC的新药。
